<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594135</url>
  </required_header>
  <id_info>
    <org_study_id>ICG190-001</org_study_id>
    <nct_id>NCT04594135</nct_id>
  </id_info>
  <brief_title>Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies</brief_title>
  <acronym>CD5CAR-T</acronym>
  <official_title>Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iCell Gene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iCAR Bio Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iCell Gene Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, interventional, single arm, open label, treatment study to evaluate the&#xD;
      safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T&#xD;
      cell lymphoma or leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti- CAR is a chimeric antigen receptor immunotherapy treatment designed to treat&#xD;
      lymphoma/leukemia expressing CD5 antigen. CD5+ T cell lymphomas or leukemia are a subset of&#xD;
      leukemias and lymphomas that are positive for the surface protein CD5. The purpose of this&#xD;
      study is to evaluate the efficacy and safety of anti-CD5 CAR T cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events after anti-CD5 CAR T cells cell infusion</measure>
    <time_frame>2 years particularly the first 28 days after infusion</time_frame>
    <description>Determine the toxicity profile of anti-CD5 CAR T cell therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Disease Free Survival (DFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-Free Survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>T-cell Acute Lymphoblastic Leukemia</condition>
  <condition>T-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>anti-CD5 CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-CD5 CAR T cells</intervention_name>
    <description>anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells</description>
    <arm_group_label>anti-CD5 CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent; Patients volunteer to participate in the research&#xD;
&#xD;
          2. Diagnosis is mainly based on the World Health Organization (WHO) 2008&#xD;
&#xD;
          3. Patients have exhausted standard therapeutic options&#xD;
&#xD;
          4. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped&#xD;
             for more than 1 weeks&#xD;
&#xD;
          5. Female must be not pregnant during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients declining to consent for treatment&#xD;
&#xD;
          2. Prior solid organ transplantation&#xD;
&#xD;
          3. Potentially curative therapy including chemotherapy or hematopoietic cell transplant&#xD;
&#xD;
          4. Any drug used for GVHD must be stopped &gt;1 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyu Zhang, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin G Pinz, MS</last_name>
    <phone>6315386218</phone>
    <email>kevin.pinz@icellgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhang, MD/PhD</last_name>
      <email>Hongyu.Zhang@pkuszh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-CD5 CAR</keyword>
  <keyword>T cell leukemia/lymphoma</keyword>
  <keyword>T-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

